Progesterone

Generic Name
Progesterone
Brand Names
Bijuva, Crinone, Endometrin, Prochieve, Prometrium
Drug Type
Small Molecule
Chemical Formula
C21H30O2
CAS Number
57-83-0
Unique Ingredient Identifier
4G7DS2Q64Y
Background

Progesterone is a hormone that occurs naturally in females, and is essential for endometrial receptivity, embryo implantation, and the successful establishment of pregnancy. A low progesterone concentration or an insufficient response to progesterone can cause infertility and pregnancy loss . Progesterone is used in various contraceptive preparations to prevent ovulation and fertilization , as well as in other formulations to promote and support pregnancy. Please see Medroxyprogesterone acetate, Megestrol acetate, Dydrogesterone and Hydroxyprogesterone entries for information on various other forms of progesterone.

Pharmaceutical progesterone is made from a plant source as a starting material and is chemically identical to progesterone of human ovarian origin . Progesterone is available in gelatinized capsule form, vaginal gel form, tablet form, vaginal insert form, and injection form, all used for various purposes .

Indication

Gelatinized capsules

The gelatinized capsules are indicated for use in the prevention of endometrial hyperplasia in non-hysterectomized postmenopausal women who are receiving conjugated estrogens tablets. They are also indicated for use in secondary amenorrhea .

Vaginal gel

Progesterone gel (8%) is indicated as progesterone supplementation or replacement as part of an Assisted Reproductive Technology (“ART”) treatment for infertile women with progesterone deficiency. The lower concentration progesterone gel (4%) is used in the treatment of secondary amenorrhea, with the use of the 8% concentration if there is no therapeutic response to the 4% gel .

Vaginal insert

This form is indicated to support embryo implantation and early pregnancy by supplementation of corpus luteal function as part of an Assisted Reproductive Technology (ART) treatment program for infertile women .

Injection (intramuscular)

This drug is indicated in amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer .

Tablets, contraceptive

The tablet form of progesterone in contraceptive formulations is indicated for the prevention of pregnancy .

Associated Conditions
Abnormal Uterine Bleeding, Amenorrhea, Endometrial hyperplasia caused by conjugated estrogen, Moderate to Severe Vasomotor Symptoms, Pregnancy, Secondary Amenorrhea, Recurrent spontaneous preterm birth
Associated Therapies
Assisted Reproductive Technology therapy

Relationship Between the Menstrual Cycle and Heart Disease in Women

First Posted Date
2012-03-07
Last Posted Date
2017-03-22
Lead Sponsor
Oregon Health and Science University
Target Recruit Count
5
Registration Number
NCT01546454
Locations
🇺🇸

Oregon Health & Sciences University, Department of Obstetrics and Gynecology, Women's Health Research Unit, Portland, Oregon, United States

Vaginal Progesterone for Prevention of Preterm Birth After an Episode of Preterm Labor

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2012-02-01
Last Posted Date
2015-04-22
Lead Sponsor
University Medical Centre Ljubljana
Target Recruit Count
30
Registration Number
NCT01523483
Locations
🇸🇮

Univerity Medical Centre Ljubljana, Ljubljana, Slovenia

Vaginal Progesterone Versus Progesterone in Oil in Donor Egg Recipient In Vitro Fertilization Cycles Utilizing Vitrified Donor Eggs

Phase 4
Completed
Conditions
Interventions
First Posted Date
2011-11-04
Last Posted Date
2011-11-04
Lead Sponsor
Fertility Centers of Illinois
Target Recruit Count
10
Registration Number
NCT01465373
Locations
🇺🇸

Fertility Centers of Illinois, Chicago, Illinois, United States

Suppression of Daytime and Nighttime Luteinizing Hormone Frequency by Progesterone

First Posted Date
2011-09-02
Last Posted Date
2023-11-02
Lead Sponsor
University of Virginia
Target Recruit Count
40
Registration Number
NCT01428089
Locations
🇺🇸

Center for Research in Reproduction, University of Virginia, Charlottesville, Virginia, United States

Assessment of Sensitivity of the Hypothalamic GnRH Pulse Generator to Estradiol and Progesterone Inhibition

First Posted Date
2011-09-02
Last Posted Date
2020-12-30
Lead Sponsor
University of Virginia
Target Recruit Count
3
Registration Number
NCT01428245
Locations
🇺🇸

Center for Research in Reproduction, University of Virginia, Charlottesville, Virginia, United States

Effects of Androgen Blockade on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone

First Posted Date
2011-09-02
Last Posted Date
2018-06-04
Lead Sponsor
University of Virginia
Target Recruit Count
4
Registration Number
NCT01428193
Locations
🇺🇸

Center for Research in Reproduction, University of Virginia, Charlottesville, Virginia, United States

Effect of Metformin on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone

First Posted Date
2011-09-01
Last Posted Date
2021-01-08
Lead Sponsor
University of Virginia
Target Recruit Count
25
Registration Number
NCT01427595
Locations
🇺🇸

Center for Research in Reproduction, University of Virginia, Charlottesville, Virginia, United States

Assessment of the Sensitivity of the Hypothalamic GnRH Pulse Generator to Estradiol and Progesterone Inhibition

Not Applicable
Active, not recruiting
Conditions
Interventions
First Posted Date
2011-08-30
Last Posted Date
2023-11-02
Lead Sponsor
University of Virginia
Target Recruit Count
60
Registration Number
NCT01425541
Locations
🇺🇸

Center for Research in Reproduction, Charlottesville, Virginia, United States

Estrogen Sensitivity and Ovulatory Dysfunction in Obesity

First Posted Date
2011-06-27
Last Posted Date
2015-04-20
Lead Sponsor
University of Colorado, Denver
Target Recruit Count
30
Registration Number
NCT01381016
Locations
🇺🇸

University of Colorado, Anschutz Medical Campus, Aurora, Colorado, United States

© Copyright 2024. All Rights Reserved by MedPath